Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UMN Pharma’s Avian Flu Vaccine Trial Confirms Efficacy and Safety

This article was originally published in PharmAsia News

Executive Summary

Akita based UMN Pharma announced that a clinical trial conducted in 2008 on 125 healthy males aged 20 to 40 in Tokyo confirmed efficacy and safety of UMN-0501, a H5N1 type avian flu vaccine. The company will release the details of the trial result at the World Health Organization's avian flu conference in February. UMN Pharma also plans to start a new trial for the flu vaccine with added effective ingredients within the year. UMN-0501 has been designated an orphan drug in Japan and the company receives assistance to cover development expenses. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel